The effectiveness of empagliflozin in patients with acute myocardial infarctio

Phase 2

Recruiting

• Conditions: Acute myocardial infarction.; Subsequent ST elevation (STEMI) myocardial infarction of unspecified site; I22.9

• Registration Number: IRCT20230501058035N2
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 354

Inclusion Criteria

Diagnosis of ST elevation MI acute myocardial infarction by a cardiologist based on clinical variables and ECG
Glomerular filtration rate (rGFR) more than 30
Systolic blood pressure before the first dose of the drug more than 110
Diastolic blood pressure before the first dose of medicine more than 70
The first dose of drug administration less than 72 hours after the occurrence of an acute stroke

Exclusion Criteria

People with diabetes other than type 2
History of diabetic ketoacidosis
Hemodynamic instability caused by intravenous administration of catecholamine, calcium sensitizers, or phosphodiesterase inhibitors
Acute symptomatic urinary tract infection
Genital infection
Continuous treatment with SGLT2 inhibitors
Being treated with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin) four weeks before the screening visit.
Known allergy to SGLT-2 inhibitors
Severe hypoglycemia in the last six months treated with insulin or sulfonylurea
Symptomatic acute urinary tract infection (UTI) or genital infection
Patients currently receiving treatment with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin).

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cardiovascular function in echocardiography. Timepoint: The systolic and diastolic function of the left ventricle of the heart is measured in two stages (before the intervention and then 4 to 6 weeks after discharge from the hospital). Method of measurement: Using an echocardiography device using the Simpson method.;Quality of life with SF36 questioner. Timepoint: Before and after interventions. Method of measurement: SF36 questioner.